

Forenede Kongerige, Det-Bristol: Virksomhed i forbindelse med  
patologi

OJ S 21/2020 30/01/2020

Bekendtgørelse med henblik på frivillig forudgående gennemsigthed

Tjenesteydelser

**Retsgrundlag:**

Direktiv 2014/24/EU

## Del I: Ordregivende myndighed/enhed

---

### I.1. Navn og adresser

Officielt navn: North Bristol NHS Trust

Postadresse: Southmead Road, Bristol

By: Bristol

NUTS-kode: UKK11 Bristol, City of

Postnummer: BS10 5NB

Land: Det Forenede Kongerige

Kontaktperson: Martin Strawson

E-mail: [martin.strawson@UHBristol.nhs.uk](mailto:martin.strawson@UHBristol.nhs.uk)

Telefon: +44 1173420815

**Internetadresse(r):**

Overordnet internetadresse: <https://www.nbt.nhs.uk/>

### I.4. Type ordregivende myndighed

Anden type: NHS trust

### I.5. Hovedaktivitet

Sundhed

## Del II: Genstand

---

### II.1. Udbuddets omfang

#### II.1.1. Betegnelse

Procurement of a Large Throughput DNA Sequencer

Sagsnr.: BWPCCL001501

#### II.1.2. Hoved-CPV-kode

85111800 Virksomhed i forbindelse med patologi

#### II.1.3. Kontrakttype

Tjenesteydelser

#### II.1.4. Kort beskrivelse

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per

run, providing flexibility across a broad range of applications and study sizes. The NovaSeq 6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

#### **II.1.6. Oplysninger om delkontrakter**

Kontrakten er opdelt i delkontrakter: nej

#### **II.1.7. Udbuddets samlede værdi**

Værdi eksklusiv moms: 779 625,00 GBP

### **II.2. Beskrivelse**

#### **II.2.2. Supplerende CPV-kode(r)**

85111000 Hospitalsvirksomhed

#### **II.2.3. Udførelsessted**

NUTS-kode: UKK11 Bristol, City of

#### **II.2.4. Beskrivelse af udbuddet**

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

#### **II.2.5. Tildelingskriterier**

Kvalitetskriterium - Navn: Quality / Vægtning: 90

Pris - Vægtning: 10

## II.2.11. Oplysninger om optioner

Optioner: nej

## II.2.13. Oplysninger om EU-midler

Udbuddet vedrører et EU-finansieret projekt og/eller program: nej

## II.2.14. Yderligere oplysninger

### Del IV: Procedure

---

#### IV.1. Beskrivelse

##### IV.1.1. Proceduretype

Tildeling af kontrakt uden forudgående offentliggørelse af en udbudsbekendtgørelse i Den Europæiske Unions Tidende i tilfældene anført nedenfor

- Udbuddet er ikke omfattet af direktivet

Forklaring:

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

##### IV.1.3. Oplysninger om rammeaftale

##### IV.1.8. Oplysninger om GPA-aftalen om offentlige udbud

Dette udbud er omfattet af GPA-aftalen: nej

#### IV.2. Administrative oplysninger

## Del V: Kontrakt-/koncessionstildeling

---

### Betegnelse:

Procurement of Large High Throughput DNA Sequencer

### V.2. Kontrakt-/koncessionstildeling

#### V.2.1. Dato for beslutningen om kontrakttildeing

28/01/2020

#### V.2.2. Oplysninger om tilbud

Kontrakten er blevet tildelt en sammenslutning af økonomiske aktører: nej

#### V.2.3. Kontrahentens/Koncessionshavers navn og adresse

Officielt navn: Illumina Cambridge Ltd

Postadresse: Chesterford Research Park, Little Chesterford

By: Saffron Walden

NUTS-kode: UKI London

Postnummer: CB10 1XL

Land: Det Forenede Kongerige

Kontrahenten/koncessionshaveren bliver en SMV: ja

#### V.2.4. Oplysninger om kontraktens/delkontraktens/koncessionens værdi

Kontraktens/delaftalens/koncessionens samlede værdi: 779 625,00 GBP

#### V.2.5. Oplysninger om underentreprise

## Del VI: Supplerende oplysninger

---

### VI.3. Yderligere oplysninger

### VI.4. Klageprocedurer

#### VI.4.1. Organ med ansvar for klageprocedurerne

Officielt navn: Bristol and Weston Purchasing Consortium

Postadresse: Level 3, Whitefriars, Lewins Mead

By: Bristol

Postnummer: BS1 2NT

Land: Det Forenede Kongerige

E-mail: [martin.strawson@UHBristol.nhs.uk](mailto:martin.strawson@UHBristol.nhs.uk)

#### VI.4.2. Organ med ansvar for mæglingsprocedurerne

Officielt navn: Bristol and Weston Purchasing Consortium

Postadresse: Level 3, Whitefriars, Lewins Mead

By: Bristol

Postnummer: BS1 2NT

Land: Det Forenede Kongerige

#### VI.4.4. Tjeneste, hvor der kan fås oplysninger om klageproceduren

Officielt navn: Bristol and Weston Purchasing Consortium

Postadresse: Level 3, Whitefriars, Lewins Mead

By: Bristol

Postnummer: BS1 2NT

Land: Det Forenede Kongerige

**VI.5. Dato for afsendelse af denne bekendtgørelse**

28/01/2020